StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report released on Monday morning. The firm issued a sell rating on the stock.

Oragenics Stock Performance

Shares of NYSE OGEN opened at $0.32 on Monday. The stock has a market cap of $1.79 million, a price-to-earnings ratio of -0.04 and a beta of 0.49. Oragenics has a fifty-two week low of $0.28 and a fifty-two week high of $7.74. The firm’s 50-day simple moving average is $0.45 and its 200 day simple moving average is $1.06.

Oragenics (NYSE:OGEN) last posted its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new position in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics at the end of the most recent quarter. Institutional investors and hedge funds own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.